• AtriCure, Inc. recently reported its second-quarter 2026 results, with revenue of US$153.6 million and net income of US$8.96 million, and issued full‑year 2026 guidance calling for US$602 million to US$610 million in revenue and net income per share of US$0.05 to US$0.13.
• The shift from a net loss in the prior-year quarter to positive earnings in both the quarter and year-to-date period marks a clear profitability inflection that could reshape how investors view AtriCure’s ability to translate sales growth into bottom‑line results.
• With AtriCure now producing quarterly profits and setting full‑year guidance, we’ll examine how this earnings inflection affects its investment narrative.

The latest GPUs need a type of rare earth metal called Neodymium and there are only 29 companies in the world exploring or producing it. Find the list for free.

AtriCure Investment Narrative Recap

To own AtriCure, you need to believe that its cardiac surgery and pain management devices can sustain healthy procedure volumes while gradually improving profitability. The shift to profitable quarters and explicit 2026 EPS guidance sharpens the near term focus on whether margins can hold up as pulsed field ablation competition pressures parts of the ablation franchise. That same competition, along with the cost of funding clinical trials and commercialization, remains the most important risk in the story right now.

The most relevant recent announcement is AtriCure’s 2026 guidance for US$602 million to US$610 million in revenue and US$0.05 to US$0.13 in net income per share. Coming alongside a profitable second quarter and first half, this brackets how management currently sees the balance between growth investments, ongoing trial costs like BoxX NoAF, and operating leverage. For anyone watching catalysts such as international expansion and trial readouts, this guidance offers a concrete earnings yardstick for the year.

Yet even with this new profitability milestone, the competitive pressure from emerging PFA catheter technologies is something investors should be aware of as...

AtriCure’s narrative projects $784.1 million revenue and $32.5 million earnings by 2029. This implies 12.4% yearly revenue growth and about a $37.1 million earnings increase from -$4.6 million today.

Uncover how AtriCure's forecasts yield a $47.00 fair value, a 34% upside to its current price.

Exploring Other Perspectives

Before this earnings beat, the most optimistic analysts were assuming revenue could reach about US$805 million and earnings about US$45.7 million by 2029, which paints a far more upbeat picture than the baseline risk that PFA competition might weigh on AtriCure’s ablation business, and this Q2 profit inflection could either reinforce or challenge that view depending on how sustainable you think these margins really are.

Explore 2 other fair value estimates on AtriCure - why the stock might be worth less than half the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your AtriCure research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free AtriCure research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AtriCure's overall financial health at a glance.

Ready For A Different Approach?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.